Folia Health and Argenx Partner on Groundbreaking Real-World Evidence Study for CIDP Patients

Folia Health has announced a pioneering collaboration with argenx ($ARGX) to launch the first-of-its-kind at-home observational real-world evidence initiative designed to capture the true disease burden experienced by patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and their caregivers. The innovative study leverages Folia Health's proprietary home-reported outcomes platform to gather granular data on symptom severity, treatment utilization, and daily disease management directly from participants over a six-month period—a methodological approach that represents a significant departure from traditional clinical trial structures.

This collaboration underscores a broader industry shift toward patient-centric data collection and real-world evidence generation, particularly in rare and ultra-rare neurological conditions where conventional clinical trial infrastructure may not adequately capture the lived experience of disease. The initiative addresses a critical gap in understanding the unmet medical needs of CIDP patients, a population that has historically been underrepresented in robust observational research frameworks.

Bridging the Evidence Gap in CIDP Management

CIDP, a rare autoimmune disorder affecting the peripheral nervous system, presents significant diagnostic and management challenges due to its heterogeneous presentation and the variable response to available therapies. The disease burden extends far beyond laboratory measurements and standardized clinical assessments, encompassing profound impacts on patients' physical function, emotional well-being, and quality of life—dimensions that traditional clinical endpoints often fail to capture adequately.

Folia Health's home-reported outcomes platform represents a technological advancement in how real-world health data is collected. Rather than relying on sporadic in-clinic assessments or retrospective patient recall, the app-based approach enables continuous, longitudinal data capture directly from patients' home environments. This methodology offers several distinct advantages:

• Reduced recall bias: Real-time symptom reporting minimizes memory-related inaccuracies
• Enhanced granularity: Captures daily fluctuations in disease symptoms and functional status
• Caregiver perspectives: Includes insights from family members who often bear significant disease-related burden
• Treatment utilization patterns: Documents actual medication use and management strategies in real-world settings
• Accessibility: Removes geographic and mobility barriers that often prevent CIDP patients from participating in research

For argenx ($ARGX), which markets FABHALTA (efgartigimod alfa), a therapeutic option for CIDP, this real-world evidence initiative provides a critical pathway to understanding treatment outcomes beyond controlled trial environments. The data generated could inform clinical practice guidelines, support reimbursement discussions with payers, and validate the true clinical value of existing and pipeline therapies in CIDP management.

Market Context and Competitive Landscape

The CIDP therapeutic market has expanded significantly following the approval of several new disease-modifying agents over the past five years. argenx's FABHALTA represents one of the most recent additions to this evolving treatment landscape, competing alongside intravenous immunoglobulin (IVIG) infusions, plasmapheresis, and other immunosuppressive approaches. The market remains fragmented, with substantial variation in treatment practices across different healthcare systems and geographic regions.

Real-world evidence has become increasingly influential in pharmaceutical decision-making and regulatory discussions. Health authorities, including the FDA and EMA, have formally acknowledged the value of real-world data in validating efficacy claims, identifying safety signals, and understanding how therapies perform outside controlled trial conditions. This regulatory evolution has created opportunities for biopharmaceutical companies to differentiate their products through robust real-world evidence programs.

Folia Health's emergence as a platform provider reflects broader digitalization trends in healthcare data collection. Competing platforms and research organizations are similarly investing in home-based monitoring technologies and patient-reported outcome solutions, recognizing the commercial and clinical value of decentralized data infrastructure. This competitive landscape suggests that organizations leveraging innovative data collection methodologies may gain competitive advantages in demonstrating product value to payers and healthcare providers.

The six-month study duration is particularly noteworthy, as it extends beyond typical acute-phase clinical trials and provides sufficient time to assess sustained treatment effects, medication adherence patterns, and emerging quality-of-life improvements that become apparent only with longer observation periods.

Investor Implications and Strategic Significance

For argenx shareholders, this real-world evidence initiative represents a strategic investment in post-market surveillance and commercial positioning. Robust real-world data can significantly strengthen FABHALTA's market penetration by:

• Demonstrating clinical value: Providing compelling evidence of symptom improvements and functional benefits to neurologists and patient advocacy groups
• Supporting market expansion: Offering data to payers for reimbursement negotiation and establishing a clear value proposition relative to competing therapies
• Informing future development: Identifying subpopulations that benefit most from treatment and potential combination therapy opportunities
• Building patient confidence: Generating testimonial evidence and treatment outcome data that resonates with patient communities

The initiative also carries broader implications for the biopharmaceutical industry's approach to evidence generation. Companies that successfully implement decentralized, patient-centric data collection methodologies may establish competitive moats through superior real-world evidence databases. These data assets can support multiple commercial and clinical objectives, from marketing and reimbursement to regulatory submissions and academic collaboration.

For Folia Health as a commercial entity, this partnership with a major pharmaceutical company validates its platform technology and positions it as a trusted partner for rare disease research. Successful execution of this CIDP study could lead to additional collaborations across argenx's broader pipeline and with competing biopharmaceutical organizations seeking similar real-world evidence generation capabilities.

The regulatory environment also appears favorable for such initiatives. As healthcare systems increasingly emphasize value-based care and outcomes-driven reimbursement, real-world evidence that quantifies symptom burden, treatment utilization, and quality-of-life impacts will likely become increasingly important to coverage decisions and pricing negotiations. Companies that proactively generate this evidence gain negotiating advantages with payers.

Looking Ahead: The Future of Patient-Centric Evidence

This collaboration between Folia Health and argenx ($ARGX) exemplifies an important evolution in how pharmaceutical companies validate and communicate the value of their therapies. By moving data collection from clinical research centers directly into patients' homes, the initiative captures authentic disease experiences and treatment outcomes in real-world contexts. The six-month longitudinal design and inclusion of caregiver perspectives promise to deliver unprecedented insights into the true disease burden of CIDP and the meaningful benefits that modern therapeutics can provide.

As rare disease communities increasingly demand evidence that reflects their lived experiences, and as payers grow more sophisticated in evaluating the actual clinical value of expensive therapies, initiatives like this real-world evidence study are likely to become standard industry practice rather than differentiating innovations. Early leaders in implementing such programs, however, will likely establish significant competitive advantages through superior data quality, deeper patient engagement, and more compelling evidence narratives to drive clinical adoption and reimbursement success.